Pharmacoeconomics theory and practice  КРИТЕРИИ ЭФФЕКТИВНОСТИ В ФАРМАКОЭКОНОМИЧЕСКОМ АНАЛИЗЕ  РЕЗУЛЬТАТЫ РОССИЙСКИХ ФАРМАКОЭКОНОМИЧЕСКИХ ИССЛЕДОВАНИЙ №3 №3 45 RUSSIAN STUDIES Summary: Control of bronchial asthma (BA) is a key principle of disease treatment. One of the factors resulting in uncontrolled BA is incorrect use of an inhalation device and, as a consequence, low adherence to therapy. According to research data, up to 94% of patients, depending on the type of delivery system, make mistakes during application, resulting in inconsistent dosage and reduced efficacy. These factors may contribute toward an increase in costs of the healthcare system and decrease in the quality of life of patients. For example, an unapproved change of the inhaler may lead to reduced BA control and, as a result, growing expenses for medical services despite lower initial costs of pharmacotherapy. Availability of a wide range of medications and devices for delivering them, as well as limited financial resources of the healthcare system inspired a pharmacoeconomic assessment of various schemes of BA therapy. According to the cost analysis results, the provided amounts of direct and indirect costs for one-year therapy with Symbicort ® Turbuhaler ® as the sole inhaler is on average 4.5% lower than the costs of treatment with DuoResp Spiromax ® , Formisonid-Nativ ® , Foradil Combi ® , Foster ® , Seretide ® and Seretide ® Multidisk ® . A budget impact analysis demonstrated that switching of patients from therapy with budesonis/formoterol Turbuhaler ® as the sole inhaler to therapy with Duo-Resp Spiromax ® , Formisonid-Nativ ® , Foradil Combi ® , Foster ® , Seretide ® and Seretide ® Multidisk ® entails additional average budget expenditures of RUB 4 mln per annum due to increased hospitalization frequency per 106 cases, more frequent calls for ambulance per 364 cases, more frequent visits to outpatient settings and polyclinics per 180 cases, as well as more days of temporary disability per 1 862 days -every figure given per 1,000 patients with BA. It is, therefore, clinically and economically reasonable that patients initially receiving Symbicort ® Turbuhaler ® as a support maintenance therapy to continue therapy using the same medication.
Introduction
The main objective of treating bronchial asthma (BA) of any severity is to achieve and maintain control over clinical manifestations of the disease and reduce future risks of exacerbations [1] . An important task is to prevent exacerbations as they constitute the cause of disease progression leading to decreased quality of life and significant increase in BA treatment costs. The inhalation system of delivery plays a significant role in achieving control of BA. However, inhalation devices are manifold and each has its own specifics and requires individual training in using it. Incorrect inhalation technique may cause not only inconveniences in using the device leading to low adherence to the therapy, but also variable dosage and side effects. In view of the above, it can be concluded that the efficacy of BA therapy depends on the choice of the inhalation device and may lower after unauthorized replacement of the device [3, 10] .
A replacement of the inhalation device without consultation with the physician may lead to: incorrect use of the inhaler, low adherence, decrease of pulmonary deposition, increase in exacerbations/lower control of the pulmonary disease [2] . The effects of unauthorized change in the medication delivery device on the BA control was also studied in detail by Thomas M. et al. (Fig. 2) [3] . A cohort study which lasted for 2 years and compared 824 patients, who changed the type of device for ICS delivery without consultations with physicians, with 824 patients, who continued using their usual devices. The results demonstrated that a switch to a different inhalation device leads to an increased number of patients with uncontrolled BA and decreased number of patients with controlled asthma [3] .
Besides, the consequences of an unauthorized switch to a different inhaler or inhalation device should be compared to the arguments in favor of changing the inhalation device without the patient's consent in terms of non-medical/budget expenses. For example, initial decrease in costs may be associated with further growth of healthcare expenses [4] . Björnsdóttir U.S. et al. [4] Systematic Review data prove that an unauthorized switch to different inhalers by patients is associated with a series of negative results of treatment -both at the individual level and at the level of the organization. These factors reducing therapy adherence may result in increased costs of the healthcare system and decreased quality of the life of patients [4] . Following the trend of reducing the expenses in the context of limited healthcare resources, additional investments designed to ensure high adherence to therapy result in reduced need for healthcare resources. On the contrary, reduced costs of purchasing medications when switching to a different inhalation device may lead to higher future healthcare expenses caused by a decrease in BA control ( Fig.1 ) [4] .
Thus, the hypothesis that a change in the inhalation device to the one included into the compensation program (based solely on economic parameters) may lead to increased need of such patient for medical assistance, thus resulting in growing healthcare expenses served the grounds for performing of this pharmacoeconomic study.
The objective of the study was defined as an assessment of the economic benefits of a change in therapy with Symbicort ® Turbuhaler ® medication to therapy with DuoResp Spiromax ® , Formisonid-Nativ ® , Foster ® , Foradil Combi ® , Seretide ® and Seretide ® Multidisk ® .
Material and methods
Based on the above listed hypothesis and study objective, we performed pharmacoeconomic assessment of using Symbicort ® Turbuhaler ® medication as maintenance and reliever therapy versus using DuoResp Spiromax ® , Formisonid-Nativ ® , Foradil Combi ® , Foster ® , Seretide ® and Seretide ® Multidisk ® .
During our study, we reviewed the following two scenarios of replacing Symbicort ® Turbuhaler ® medication with other inhalers from the standpoint of impact on achieving BA control and reducing exacerbations ( Figure 2 ). We calculated the frequency of drawing on healthcare resources for each of the scenarios on the bass of the data about the share of patients with various levels of BA control. This was the basis for calculating expenses and performing the budget impact analysis.
The first scenario was based on comparing fixed combinations of Budesonid and Formoterol used as a sole inhaler for maintenance and reliever therapy. For example, using Markov's model based on the study by Thomas M. et al. [3] , we assessed the impact of switching patients from Symbicort ® Turbuhaler ® to Formisonid-Nativ ® and DuoResp Spiromax ® medications on BA control and healthcare budget expenses. In the second scenario, we compared Symbicort ® Turbuhaler ® with other medications belonging to the group of inhaled gluco-corticosteroids in combination with long-acting beta-2-agonists (ICS/LABA): Foradil Combi ® (budesonid/ formoterol), Foster ® (beclomethasone/formoterol), Seretide ® and Seretide ® Multidisk ® (salmeterol/fluticasone). Symbicort ® medication was used as the sole inhaler (i.e., in the SMART mode -Symbicort Maintenance and Reliever Therapy). In case of using other medications, Ventolin (Salbutamol), the short-acting beta-2-agonist (SABA), was used for quick relief. All known generics/Symbicort ® analogues (characterized by the same INNs but different delivery systems) were, therefore, included into the first part of the study as reference drugs. Medications from the ICS/LABA group with the biggest market share (as per the IMS Health database) were included into the second part of the study. Foradil Combi ® was included into the second reference group despite the same INN for the following reasons: This medication is not a classic fixed combination and has no recommendations for use as maintenance and reliever therapy. Information about the number of patients achieving BA control was obtained from the NIKA trial [21, 36] . The simulation time was 1 year and hence no discount was used. According to the selected clinical trials and the pharmacoeconomic study design, the target population was defined as adult patients over 18 with a proved diagnosis of moderate to severe BA requiring 3-4 stage GINA therapy, currently using Symbicort ® Turbuhaler ® as the sole inhaler [18, 21, 36] .
Data Sources
At the first phase of the pharmacoeconomic study, we performed a data search for publications relating to the topic of the study. The search request was designed based on the following key words: "asthma", "clinical trial", "maintenance and reliever therapy", "budesonide/formoterol", "Symbicort Turbuhaler", "Symbicort SMART", "Spiromax", "Inhaler CDM", "Aerolizer", "beclomethasone/formoterol or Foster", "inhaler technique", "combined therapy", "asthma control", "compliance", "inhaler switching", "switching therapy", "exacerbations", "salmeterol/fluticasone or Seretide". For reviewing publications, data search was performed in the following databases: "Rossiyskaya Meditsina" (Russian Medicine) database of the Central Scientific Medical Library of I.M. Sechenov First Moscow State Medical University, scientific electronic library еlibrary.ru. We also used free data search resources such as Yandex, Google, etc. The search was based on the following key words: "bronchial asthma", "combined therapy", "inhaled gluco-corticosteroids", "ICS/LABA", "bronchial asthma control", "budesonide/formoterol", "Symbicort Turbuhaler", "SMART", "inhaler switching", "DuoResp Spiromax", "Fomisonid -Nativ", "beclomethasone/ formoterol", "Foster", "salmeterol/fluticasone", "Seretide", "Foradil Combi", "Aerolizer", "exacerbations", etc.
During the search, more than 1 000 publications were identified as meeting the search criteria. Then we excluded the duplicate publications and research materials irrelevant to BA therapy with budesonide/formoterol as the sole inhaler and ICS/LABA medications described above. We also excluded publications of preliminary results from further search. In order to be included into the study, the "results" section should have contained data on the number/frequency of exacerbations detailing relevant outcomes, level of BA control (shares of patients achieving control), death rate, side effects frequency or quality of life for each of the compared alternatives. The level of evidence was determined according to the grading scales used to assess the levels of evidence of the results of clinical trials of medications and evidence credibility levels. Studies with A or B level of evidence (evidence summarized in a systematic review or meta-analysis and evidence from prospective RCTs, respectively) were selected in the first place. In the absence of the above, studies with lower level of evidence were analyzed. The Results were summarized in a special table for further analysis and the assessed by experts. After such screening, we selected 22 publications for further review ( Table  1 ). All publications referred to patients with moderate to severe BA requiring 2-4 stages of GINA therapy. As we can see from the Table, the majority of authors, e.g., Stallberg B. et al. [32] , Bateman E. D. et al. [18] , Reddel H. K. et al. [19] and others compare Symbicort ® Turbuhaler ® in the SMART mode with fixed combinations of medications containing budesonide/formoterol. In most cases, the respective medication was delivered with a Turbuhaler ® device. When the alternative therapy was selected based on the best clinical practices (standard therapy) -Demoly P. et al. [20] and Sears M. R. et al., 2008 [22] , the researchers did not provide any data about specific medications from the ISCS/LABA group. The publications assessing the inhaling technique which we managed to find (Sandler N. et al., 2016 [38] and Rootmensen G. N. et al., 2010 [40] ) did not cover all analyzed devices.
We did not find any studies which would assess the efficacy and safety of generics/ Symbicort ® Turbuhaler ® analogues used for maintenance and reliever therapy. As a consequence, we used the Markov modeling method, which demonstrated the impact of switching patients to an analogous inhalation device. We used the previously described study Thomas M. et al. [3] to assess the degree of impact of a change in the inhalation device. Based on the study design, the patients were achieving BA control with Symbicort ® Turbuhaler ® administered in the SMART mode. That is why we used BA control data from study Bateman E. D. et al. [18] as a natural progression for building the model. The study won the priority over the other meta-analyses as it contained data on the probability of shifting from one level of BA control to a different level thereby optimizing the process of building the model.
To perform a pharmacoeconomic assessment under the second scenario, we selected the Russian study NIKA [21, 36] as the only alternative reflecting the relevant schemes of comparison to the fullest extent possible. The distribution of shares of patients by levels of BA control was as follows: Symbicort ® Turbuhaler ® in SMART mode -22.4%, salmeterol/fluticasone -10.6%, any fixed combinations -9.7%, any free combinations -8.6% [21, 36] . Because no separate numerical data for each of the free/fixed combinations covered by the study were provided, we proceeded from the assumption that the values specified for the overall group corresponded to those for Foradil Combi ® and Foster ® . We also made the assumption that salmeterol/fluticasone delivered with a dosing aerosol inhalation device (DAI) or powder-based inhalation device (PBI) (Seretide ® and Seretide ® Multidisk ® ) were equally effective. Our assumption was based on the lack of data to the contrary.
It should also be noted that, during the data search, we did not find any studies with a simultaneous comparison of alternative medications in question, either for the first or second scenario, by frequency and type of adverse events (e.g., pharyngitis rate, nausea rate, etc.). For that reason, for the purposes of our pharmacoeconomic study, we used the adverse effects frequency provided in patient information leaflets of the compared alternatives [11] [12] [13] [14] [15] [16] [17] . 
Modeling
Due to the lack of long-term data on the compared therapy schemes under the first scenario, the economic evaluation was performed using the probabilistic Markov switching model, which is built in Microsoft Excel and applied to modeling patient switching between different health statuses. Figure 3 presents Markov model structure.
Probabilities of BA state transition for therapy with Symbicort ® Turbuhaler ® (Table 20 were defined based on the study by Bateman E.D. et al. [18] , as well as the duration of the model cycle, which made 1 week. (Table 2 ) Probabilities of BA state transition for the scheme of switching to alternative medications were calculated based on the Bateman E. D. et al. [18] study using data from the study by Thomas M. et al. [3] .
Because the model provides for time horizon selection, loss of patients in the population should be taken into account. Mortality was assessed based on the statistics of mortality of adults (age 18-90 years) in Russia [6] . Based on the mortality data broken down by age and sex, the weighted average coefficients for each age of patients were calculated in consideration of the duration of 1 cycle of the Markov model. For obvious reasons, this value turned out to be the same for all types of therapy.
Cost analysis
During the next stage of the pharmacoeconomic study, based on the data about the shares of patients with various levels of BA control, data about the rate of using healthcare resources, costs of medications and certain types of medical aid, and also with account of costs associated with temporary disability, the aggregate costs of using the compared medications were calculated.
First, the costs of pharmacotherapy with the compared medications were analyzed. The dosing schedule for maintenance therapy was defined by the Basic Prescribing Information (BPI) for the compared medications [11] [12] [13] [14] [15] [16] [17] . For reliever therapy, the exact number of puffs of rescue medications was set based on Sears M. R. et al., 2008 [22] study data and made 0.94 puffs
No.
Author, year Brief description / design, duration Comparison alternatives Rescue medications Efficacy criterion 19 Terzano C. et al., [37] prospective study in real clinical practice (n = This assumption in favor of alternative medications was made given the lack of other data proving the impact of the specific Budesonide/Formoterol delivery device on the number of doses used as reliever therapy for compensation of asthmatic attacks. The number of Salbutamol doses amounted to 1.09 puffs per day [22] when administered together with Foradil ® Combi ® , Foster, Seretide ® and Seretide ® Multidisk ® .
To build a reference case for the model, the most common pharmaceutical forms were selected for every medication under the two scenarios on the basis of the data search performed. All Budesonide/Formoterol medications were used in the sole inhalation device mode (Tables 3, 4 ). During the next phase, we analyzed the costs associated with using healthcare resources. The frequency and severity of exacerbations depend on the level of BA control. Based on that, we calculated the costs of hospitalization, calling the ambulance and additional visits to the physician. Costs of oral corticosteroids courses were not accounted for due to unavailability of data. The frequency of medical services delivery during exacerbation stage per patient/year depending on the level of BA control was obtained from publication by Demko I.V. [5] :
For Scenario 1, we assumed that the frequency of using the resources for partially controlled BA equals the frequency for uncontrolled BA due to unavailability of additional data. Then, using the rates published by the Federal Compulsory Medical Insurance Fund for Moscow (as of December 2016) [9] covering visits to physician within the outpatient system, calling the ambulance and delivering in-patient care for completed therapy case, and applying the above described frequency of medical services delivery, we received the respective costs for each medication.
After that, we assessed the costs of side effects compensation, the frequency and types of which were described in Basic Prescribing Information (BPI) for the compared medications [11] [12] [13] [14] [15] [16] [17] due to unavailability of the respective data in the reviewed studies. Side effects were grouped as follows depending on their frequency in accordance with the World Health Organization's (WHO) classification: very frequent (>1/10); frequent (>1/100, <1/10); infrequent (>1/1000, <1/100); rare (>1/10.000, <1/1000); very rare (<1/10.000); isolated occurrences (frequency cannot be defined). The medical aid rates were calculated based on the respective Standards, clinical recommendations, reference books, rates for completed therapy case or expert opinion, using the rates published by the Federal Compulsory Medical Insurance Fund for Moscow [9] .
During the final stage, we analyzed indirect costs of BA therapy based on the data provided by Demko I.V. [5] about the number of temporary disability days for patients with uncontrolled BA (22.8 days), as well as data about average salary in the RF and per capita GDP [7].
Thus, we received the following cost analysis results (see Tables 5 and 6 ): Based on the obtained results, it is possible to conclude that therapy with Symbicort ® Turbuhaler ® as the sole inhaler is less costly versus analogous medications (generics), as well as compared to other combinations of ICS/ LABA administered together with SABA as reliever therapy. This result is explained by lower direct cost of ambulance, in-patient and out-patient services, as well as by lower indirect costs associated with temporary disability.
Budget impact analysis
Budget impact analysis was the next phase of our study. We took into account the data about therapy duration for patients with BA to assess economic impact on the healthcare system budget in case of choosing therapy with ICS/LABA. The time interval used for our analysis was 1 year for all compared alternatives. It was assumed for the purposes of budget impact analysis calculations that it was possible to choose the number of patients.
We analyzed two hypothetical situations associated with the market share of the compared alternatives for Scenarios 1 and 2. According to the study design, in the current situation all the patients (i.e., 100%) were using Symbicort ® Turbuhaler ® as the sole inhaler, and in the simulated situation the patients switched to other inhalers with equal distribution of market shares. This calculation allowed for evaluating the budget income of unauthorized switching of patients from Budesonide/Formoterol Turbuhaler ® therapy to therapy with other ICS/LABA or to Budesonide/Formoterol therapy delivered by other inhalation devices. The calculation was done for 1,000 patients.
The budget impact analysis resulted in the following values of additional budget expenses presented in Figures 4 and 5 for Scenario 1 and Scenario 2, respectively. In addition, the data received were expressed in the change of frequency of drawing the healthcare system resources.
Therefore, switching of 1,000 patients from Symbicort® Turbuhaler ® to its generics/analogues and to other medications of the ICS/LABA group resulted in additional budget expenditures of RUB 3,865,843 and RUB 4,913,273 under Scenario 1 and Scenario 2, respectively -due to the increased number of hospitalization cases by 92 and 120 cases per year (c/y), unplanned visits to physicians by 156 and 203 c/y, calls for ambulance by 316 and 412 c/y, as well as increase in number of temporary disability days by 1,617 and 2,107 c/y, respectively. All the above evidences in favor of the hypothesis underpinning this pharmacoeconomic study: unauthorized switching of patients to cheaper analogues results in higher expenses of the healthcare system due to expensive compensation of the arising exacerbations despite lower costs of pharmacotherapy per se.
Conclusions
The pharmacoeconomic analysis of continuation of using Symbicort ® Turbuhaler ® in the bronchial asthma pharmacotherapy allowed for the following findings: 1. According to the cost analysis results, the provided amounts of direct and indirect costs for one-year therapy with Symbicort ® Turbuhaler ® as 
